Postoperative muscle weakness in a patient recently treated with infliximab

Drummond, Andrew; Williamson, R.; Silverdale, Monty; Rothwell, Matt

doi:10.1111/j.1365-2044.2007.05415.x

Cited by 6 publications

(2 citation statements)

References 9 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Drummonad at al. reported profound postoperative muscle weakness in a patient who had been treated with infliximab (35). However, reports in literature suggesting interactions between infliximab and any anaesthetic drugs are unavailable.…”

Section: Immunosuppressive Drugsmentioning

confidence: 99%

Crohn's Disease: From an Anesthetist’s Perspective

Zencirci¹

2012

Crohn's Disease

View full text Add to dashboard Cite

Crohn's Disease 104 3. Interaction beetween anti-Crohn's drugs and anesthetic drugs 3.1 Aminosalicylates Sulfasalazine and mesalamine are the two aminosalicylates used for Crohn's disease. The primary antiinflammatory, antipyretic, and analgesic actions of salicylates such as aspirin are due to blockade of prostaglandin synthesis by inhibition of the cyclooxygenase 1 and 2 enzymes. These are effective in maintaining remission in patients with mild-to-moderate diseases (4). Studies demonstrate that both mesalamine and sulfasalazine are efficacious at inducing and maintaining remission, and are often used as long-term maintenance treatments. The improved side effect profile of mesalamine has enabled the use of doses that are much higher in amount than doses possible with sulfasalazine. However, a number of cases of 5-ASA-induced nephrotoxicity have been reported in patients with inflammatory bowel disease (IBD) (5, 6). Several case reports have reported renal impairment in the forms of dose-dependent 'analgesic nephropathy', inhibition of cyclooxygenases or hypersensitivity leading to reversible interstitial nephritis in humans. The incidence of renal impairment in patients with IBD treated with 5-ASA is estimated to be one in 100 patients, and interstitial nephritis occurs in one in 500 patients (7, 8). M a h m u d e t a l , w e r e u n a b l e t o s h o w n e p h r o toxicity after six months of mesalamine treatment in patients with ulcerative colitis using a low dose of 1.2 g/day (9). Similarly, Van Staa et al, were not able to demonstrate a relationship between the dose or type of 5-ASA and the incidence of renal disease among 19,025 IBD patients on 5-ASA (10). Based on their findings, interstitial nephritis related to 5-ASA use appears to be a rare event. Although interstitial nephritis occurs infrequently, renal function can be compromised over time with the use of 5-ASA. According to a recent report, de Jong et al, did not find a significant change in creatinine clearance (CrCl) over an 11-year interval in 200 patients with Crohn's disease (11). However, the mean duration of treatment with 5-ASA was 8.6 years, much shorter than the interval that CrCl was measured. This may reflect why the decline in CrCl was reported to be within the expected physiological decline in renal function associated with aging. Fortunately, the kidneys have the capacity to regain function after an insult; thus, creatinine measurements need to be taken at the onset and end of treatment rather than time points outside of the actual treatment interval. Also, no case of interstitial nephritis was reported by same author (11). In brief, the time of development of renal impairment is variable and may be seen as late as after several years. There is also a risk of developing irreversible renal disease if not recognized early, in which discontinuation of 5-ASA could result in recovery of renal function. Monitoring serum creatinine provides an easy and inexpensive way to prevent a detrimental side effect.

show abstract

Section: Immunosuppressive Drugsmentioning

confidence: 99%

Crohn's Disease: From an Anesthetist’s Perspective

Zencirci¹

2012

Crohn's Disease

View full text Add to dashboard Cite

show abstract

“…Hypertension,[1] use of immunosuppressive agents,[2–4] eclampsia,[56] etc. can predispose to this syndrome.…”

mentioning

confidence: 99%

Posterior encephalopathy: An uncommon manifestation of calcium toxicity

Ahmed

Wai

Silverdale

2012

Indian J Endocr Metab

View full text Add to dashboard Cite

Current awareness: Pharmacoepidemiology and drug safety

2008

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Postoperative muscle weakness in a patient recently treated with infliximab

Cited by 6 publications

References 9 publications

Crohn's Disease: From an Anesthetist’s Perspective

Crohn's Disease: From an Anesthetist’s Perspective

Posterior encephalopathy: An uncommon manifestation of calcium toxicity

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About